Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Diabetes: A Meta-Analysis of Placebo-Controlled Clinical Trials | Zendy

Giuliano Tocci | Zendy; Francesco Paneni | Zendy; Francesca Palano | Zendy; Sebastiano Sciarretta | Zendy; Andrea Ferrucci | Zendy; Theodore W. Kurtz | Zendy; Giuseppe Mancia | Zendy; Massimo Volpe | Zendy

Open Access

Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers and Diabetes: A Meta-Analysis of Placebo-Controlled Clinical Trials

Author(s) -

Giuliano Tocci,

Francesco Paneni,

Francesca Palano,

Sebastiano Sciarretta,

Andrea Ferrucci,

Theodore W. Kurtz,

Giuseppe Mancia,

Massimo Volpe

Publication year - 2011

Publication title -

american journal of hypertension

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.009

H-Index - 136

eISSN - 1941-7225

pISSN - 0895-7061

DOI - 10.1038/ajh.2011.8

Subject(s) - medicine , angiotensin receptor blockers , diabetes mellitus , placebo , angiotensin converting enzyme , angiotensin ii , clinical trial , pharmacology , ace inhibitor , meta analysis , angiotensin receptor , renin–angiotensin system , endocrinology , receptor , blood pressure , pathology , alternative medicine

To determine whether the administration of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) on top of standard cardiovascular (CV) therapies may reduce the incidence of new onset diabetes (NOD) in placebo-controlled clinical trials. The effects of these drugs on CV and non-CV mortality were also tested.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research